Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)

The purpose of this initiative is to accelerate research leading to improved understanding and treatments for Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Responsive applications would propose studies of immunological mechanisms of nerve damage/dysfunction, contributing genetic/epigenetic factors, novel animal/cellular model systems, discovery of novel diagnostic or treatment response biomarkers, novel treatments or mechanisms of action of existing treatments. Key aspects of this opportunity include: • Research on GBS and CIDP to improve understanding and treatments • Studies on immunological mechanisms, genetic/epigenetic factors, and novel model systems • Discovery of novel diagnostic or treatment response biomarkers • Development of novel treatments or mechanisms of action of existing treatments • The opportunity is open to various applicant types, including public and state-controlled institutions of higher education, non-profits, and small businesses.